Person:
Ortega Hernández-Agero, María Teresa

Loading...
Profile Picture
First Name
María Teresa
Last Name
Ortega Hernández-Agero
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Farmacia
Department
Farmacología, Farmacognosia y Botánica
Area
Farmacología
Identifiers
UCM identifierScopus Author IDDialnet ID

Search Results

Now showing 1 - 1 of 1
  • Item
    Phytotherapeutic alternatives for neurodegenerative dementias: Scientific review, discussion and therapeutic proposal
    (Phytotherapy Research, 2023) Acero, Nuria; Ortega Hernández-Agero, María Teresa; Villagrasa, Victoria; León, Gemma; Muñoz Mingarro, Dolores; Castillo, Encarna; González-Rosende, María Victoria; Borrás, Silvia; Ríos, Jose Luis; Bosch-Morell, Francisco; Martínez-Solis, Isabel
    The incidence and prevalence of age-related neurodegenerative dementias have been increasing. There is no curative therapy and conventional drug treatment can cause problems for patients. Medicinal plants traditionally used for problems associated with ageing are emerging as a therapeutic resource. The main aim is to give a proposal for use and future research based on scientific knowledge and tradition. A literature search was conducted in several searchable databases. The keywords used were related to neurodegenerative dementias, ageing and medicinal plants. Boolean operators and filters were used to focus the search. As a result, there is current clinical and preclinical scientific information on 49 species used in traditional medicine for ageing-related problems, including neurodegenerative dementias. There are preclinical and clinical scientific evidences on their properties against protein aggregates in the central nervous system and their effects on neuroinflammation, apoptosis dysregulation, mitochondrial dysfunction, gabaergic, glutamatergic and dopaminergic systems alterations, monoamine oxidase alterations, serotonin depletion and oestrogenic protection. In conclusion, the potential therapeutic effect of the different medicinal plants depends on the type of neurodegenerative dementia and its stage of development, but more clinical and preclinical research is needed to find better, safer and more effective treatments.